Uso compasivo de factor VII a recombinante en pacientes con hemorragia grave

Curiel Balsera, Emilio; Santana Pareja, Victoria; Muñoz Bono, Javier.
Med. clín (Ed. impr.) ; 135(10): 476-477, oct. 2010. tab
Artículo en Español | IBECS (España) | ID: ibc-83660

Documentos relacionados

  1. In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.
  2. Factor VIIa administration in orthotopic heart transplant recipients and its impact on thromboembolic events and post-transplant outcomes.
  3. Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits.
  4. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors.
  5. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
  6. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
  7. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials.
  8. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.
  9. Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
  10. The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.